Skip to main content
Top

Open Access 18-01-2025 | Adverse Effects of Cancer Therapy | Case Report

Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review

Authors: Atsushi Takahata, Tomohito Shimada, Kana Bando, Shigeo Toyota

Published in: Annals of Hematology

Login to get access

Abstract

Epcoritamab, a bispecific T-cell engager (BiTE) antibody targeting CD3 and CD20, has shown significant efficacy in treating refractory diffuse large B-cell lymphoma (DLBCL). However, its use can lead to severe side effects, such as tumor flare. Here, we report the case of an 84-year-old male with relapsed DLBCL who developed fatal unilateral pleural effusion following Epcoritamab treatment. Initially, the patient showed a favorable response, but later developed significant pleural effusion with elevated interleukin-6 (IL-6) levels, indicating a severe inflammatory response. This suggests that Epcoritamab directly affected the pleural lesions and caused a local cytokine release syndrome (L-CRS). Despite aggressive management, including Tocilizumab and Dexamethasone, the patient’s condition worsened, leading to his death. This case underscores the importance of regular lab tests and imaging follow-ups to monitor and manage severe inflammatory reactions based on tumor location. Comprehensive monitoring protocols are needed to mitigate risks associated with novel immunotherapies. To our knowledge, this is the first reported case of fatal unilateral pleural effusion in a patient with relapsed DLBCL following Epcoritamab treatment.
Literature
1.
go back to reference Engelberts PJ, Hiemstra IH, de Jong B et al (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52:102625CrossRefPubMedPubMedCentral Engelberts PJ, Hiemstra IH, de Jong B et al (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52:102625CrossRefPubMedPubMedCentral
2.
go back to reference Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808CrossRefPubMedPubMedCentral Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808CrossRefPubMedPubMedCentral
3.
go back to reference Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol 41(12):2238–2247CrossRefPubMed Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol 41(12):2238–2247CrossRefPubMed
5.
go back to reference Cosenza M, Sacchi S, Pozzi S (2021) Cytokine release Syndrome Associated with T-Cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci 22(14):7652CrossRefPubMedPubMedCentral Cosenza M, Sacchi S, Pozzi S (2021) Cytokine release Syndrome Associated with T-Cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci 22(14):7652CrossRefPubMedPubMedCentral
6.
go back to reference Wei J, Liu Y, Wang C et al (2020) The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-hodgkin lymphoma. Signal Transduct Target Ther 5(1):134CrossRefPubMedPubMedCentral Wei J, Liu Y, Wang C et al (2020) The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-hodgkin lymphoma. Signal Transduct Target Ther 5(1):134CrossRefPubMedPubMedCentral
7.
go back to reference Tanyi JL, Stashwick C, Plesa G et al (2017) Possible compartmental cytokine release syndrome in a patient with recurrent ovarian Cancer after treatment with mesothelin-targeted CAR-T cells. J Immunother 40(3):104–107CrossRefPubMed Tanyi JL, Stashwick C, Plesa G et al (2017) Possible compartmental cytokine release syndrome in a patient with recurrent ovarian Cancer after treatment with mesothelin-targeted CAR-T cells. J Immunother 40(3):104–107CrossRefPubMed
8.
go back to reference Ding L, Hu Y, Zhao K et al (2018) Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: a case report. Med (Baltim) 97(7):e9992CrossRef Ding L, Hu Y, Zhao K et al (2018) Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: a case report. Med (Baltim) 97(7):e9992CrossRef
9.
go back to reference Jin A, Feng J, Wang Z et al (2019) Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transpl 54(7):969–972CrossRef Jin A, Feng J, Wang Z et al (2019) Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transpl 54(7):969–972CrossRef
10.
go back to reference Luan C, Zhou J, Wang H et al Case Report: local cytokine release syndrome in an Acute Lymphoblastic Leukemia Patient after Treatment with chimeric Antigen receptor T-Cell therapy: a possible model, Literature Review and Perspective. Front Immunol 2021 Jul 19:12707191 Luan C, Zhou J, Wang H et al Case Report: local cytokine release syndrome in an Acute Lymphoblastic Leukemia Patient after Treatment with chimeric Antigen receptor T-Cell therapy: a possible model, Literature Review and Perspective. Front Immunol 2021 Jul 19:12707191
11.
go back to reference Shima H, Kurosawa T, Oikawa H et al (2022) Cervical edema extending to the larynx as local Cytokine Release Syndrome following chimeric Antigen receptor T-Cell therapy in a boy with refractory Acute Lymphoblastic Leukemia. Case Rep Oncol 15(1):257–262CrossRefPubMedPubMedCentral Shima H, Kurosawa T, Oikawa H et al (2022) Cervical edema extending to the larynx as local Cytokine Release Syndrome following chimeric Antigen receptor T-Cell therapy in a boy with refractory Acute Lymphoblastic Leukemia. Case Rep Oncol 15(1):257–262CrossRefPubMedPubMedCentral
12.
go back to reference Moriyama S, Fukata M, Yokoyama T et al (2022 Mar) Case Report: Cardiac Tamponade in Association with Cytokine Release Syndrome following CAR-T cell therapy. Front Cardiovasc Med 21:9848091 Moriyama S, Fukata M, Yokoyama T et al (2022 Mar) Case Report: Cardiac Tamponade in Association with Cytokine Release Syndrome following CAR-T cell therapy. Front Cardiovasc Med 21:9848091
13.
go back to reference Nakanishi Y, Marumo Y, Ri M, Kinoshita S et al (2023) Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma. Int J Hematol 118(5):647–651CrossRefPubMed Nakanishi Y, Marumo Y, Ri M, Kinoshita S et al (2023) Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma. Int J Hematol 118(5):647–651CrossRefPubMed
14.
go back to reference Chen HH, Kuo CY, Ho CL et al (2023) Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: a case report. Med (Baltim) 102(41):e35432CrossRef Chen HH, Kuo CY, Ho CL et al (2023) Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: a case report. Med (Baltim) 102(41):e35432CrossRef
15.
go back to reference Sarfati S, Eugène Norbert M, Hérault A et al (2023 Mar) Case report: CAR-T cell therapy-induced cardiac tamponade. Front Cardiovasc Med 20:101132503 Sarfati S, Eugène Norbert M, Hérault A et al (2023 Mar) Case report: CAR-T cell therapy-induced cardiac tamponade. Front Cardiovasc Med 20:101132503
16.
go back to reference Inoue Y, Fujino T, Chinen S et al (2023) Cervical local cytokine release syndrome following chimeric Antigen receptor T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Cereus 15(5):e38905 Inoue Y, Fujino T, Chinen S et al (2023) Cervical local cytokine release syndrome following chimeric Antigen receptor T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Cereus 15(5):e38905
Metadata
Title
Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review
Authors
Atsushi Takahata
Tomohito Shimada
Kana Bando
Shigeo Toyota
Publication date
18-01-2025
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-025-06206-3

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now